Ultra-Sensitive CAR T Receptor Wipes Out Solid Tumors With Patchy CD70 Expression
CAR T-cell therapy rewrote the treatment landscape for certain blood cancers. Patients with previously untreatable leukemias and lymphomas entered lasting remissions after receiving T cells engineered to recognize CD19, a surface protein reliably displayed on malignant B cells. The challenge with solid tumors has always been different in kind, not just degree. Pancreatic, kidney, and ovarian cancers do not obligingly present a single consistent target. Their surfaces are a mosaic - some cells expressing a candidate protein abundantly, others barely at all, and some seemingly absent of it altogether.
That patchwork quality is precisely why CD70, a protein abnormally overproduced in several solid tumors, has proved frustrating as a CAR T target despite early promise. Standard CAR T cells are calibrated for strong, consistent signal. Tumor cells displaying low or zero CD70 simply go undetected, survive treatment, and repopulate the mass.
The Hidden Signal in CD70-Negative Cells
Sophie Hanina and colleagues at the University of Oxford took a closer look at what CD70-negative actually means. Using patient-derived xenograft models that faithfully recreate the uneven CD70 distribution seen in kidney cancer patients, the team found that cells labeled CD70-negative are not truly CD70-absent. They express the protein at very low levels - measurable, but well below the threshold that conventional CAR T receptors can act on.
This distinction matters enormously. If low-level CD70 is universal across tumor cells, even those classified as negative, then the problem is not target absence but target sensitivity. The therapeutic opportunity shifts from finding a better target to building a more sensitive detector.
That is exactly what the team did. They engineered a receptor they call the HLA-independent T cell receptor, or HIT receptor, specifically designed to detect and respond to very low CD70 expression. The HIT receptor operates through a different binding architecture than conventional CARs, allowing it to capture the weak signal that standard designs miss entirely.
Complete Eradication Across Three Cancer Models
In mouse and cell-based experiments, CD70-HIT cells completely and durably eradicated tumors with mixed CD70 expression in models of renal, ovarian, and pancreatic cancers. The word durably is significant here - the tumor clearance held. Conventional CAR T cells directed at CD70 did not achieve the same effect in the same models, because the cells expressing minimal CD70 survived and expanded.
The authors note that CD70 expression exists on a spectrum in all the tumor cells they examined. No subpopulation was truly silent. That finding positions CD70 as what the researchers describe as a pan-cancer target - one present at some level across more than 20 solid tumor types - provided the receptor is sensitive enough to act on it. As Hanina et al. write, their findings provide a model for identifying additional stealth targets where apparent antigen absence is really just antigen dimness that current tools cannot read.
Limits of the Current Evidence
The results so far are entirely preclinical. Mouse models and patient-derived cell lines are useful for identifying mechanisms and demonstrating proof-of-concept efficacy, but they do not reliably predict what will happen in human patients. The immune environment inside a person's tumor differs substantially from what can be recreated in a mouse, and many promising immunotherapy approaches have stalled at the transition to clinical trials.
There are also questions about selectivity. CD70 is overexpressed on tumor cells but is also found at low levels in some normal tissues, particularly activated immune cells. How the HIT receptor's extreme sensitivity handles that expression in healthy tissue will need careful evaluation before human studies begin. The authors acknowledge these considerations, framing their work as establishing a conceptual platform for this class of highly sensitive immunotherapy rather than a finished therapeutic product.
The research does offer a potentially general principle. Antigen heterogeneity has long been cited as a primary reason CAR T therapy struggles in solid tumors. If low-level expression of a target protein is actually the rule rather than the exception - present everywhere, just not always detectable - then the solution may be to engineer receptors that are better at listening rather than to search for new targets.